Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, provides an overview of immunotherapy and small molecule inhibitor regimens for the treatment of metastatic non-small cell lung cancer (NSCLC). Targeting DNA damage response pathways with PARP and ATR inhibitors have been promising, especially with data from the Phase II HUDSON study (NCT03334617) , which assessed durvalumab with olaparib or ceralasertib. Encouraging activity was observed, particularly in ATM deficient patients receiving durvalumab and ceralasertib. Additional therapies of interest include cabozantinib, a MET inhibitor and is being assessed in the COSMIC-021 trial (NCT03170960), sitravatinib and bemcentinib, a receptor tyrosine kinases (RTK) and AXL inhibitor respectively. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).